Thrombolysis in Patients With Mild Stroke
Authors:
- 1 March 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 45 (3) , 765-769
Abstract
Background and Purpose—: Apart from missing the approved time window of 4.5 hours, one frequent cause for withholding recombinant tissue plasminogen activator (rt-PA) treatment in patients with ischemic stroke is presentation with mild deficit on admission. We analyzed in a large cohort of patients whether rt-PA treatment is beneficial for this group of patients. Methods—: From a total of 54 917 patients with ischemic stroke prospectively enrolled in the Austrian Stroke Unit Registry, 890 patients with mild deficit defined as ≤5 points in the National Institutes of Health Stroke Scale treated with and without rt-PA were matched for age, sex, prestroke disability, stroke severity, hypertension, diabetes mellitus, hypercholesterolemia, stroke cause, and clinical stroke syndrome. Functional outcome was assessed using the modified Rankin Scale at 3 months. For data visualization, weighted averages of outcome differences were computed for all age severity combinations and mapped to a color. For quantification of effect sizes, numbers need to treat were calculated. Results—: rt-PA–treated patients with mild deficit had a better outcome after 3 months compared with matched cases without rt-PA treatment (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.17–1.89; P <0.001). In rt-PA–treated patients with mild deficit, the numbers need to treat ranged from 8 to 14. Improvement achieved by rt-PA treatment was observed along the entire age range. Conclusions—: In our study, intravenous rt-PA treatment was beneficial for patients with mild deficit. Given the observational nature of these results, our data might serve as an incentive for future randomized controlled trials to provide a basis for optimal patient selection.Keywords
This publication has 30 references indexed in Scilit:
- Contraindications to intravenous rtPA for acute strokeNeurology Clinical Practice, 2013
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-StrokeCirculation: Cardiovascular Quality and Outcomes, 2012
- Thrombolytic Therapy Rates and Stroke SeverityStroke, 2012
- Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic StrokeStroke, 2012
- Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen ActivatorStroke, 2011
- Outcome of Stroke With Mild or Rapidly Improving SymptomsStroke, 2007
- Recombinant Tissue Plasminogen Activator for Minor Strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study ExperienceAnnals of Emergency Medicine, 2005
- Reasons for exclusion from thrombolytic therapy following acute ischemic strokeNeurology, 2005
- Why are stroke patients excluded from TPA therapy?Neurology, 2001